Tag: Viking Therapeutics

Shares of Viking Therapeutics experienced substantial gains following the release of impressive Phase 2 trial results for its oral formulation ...

Viking Therapeutics shares are experiencing a severe sell-off, extending recent losses with a further 1.64% decline over the past trading ...

Viking Therapeutics finds itself navigating turbulent waters as its stock experiences a pronounced downward trajectory. Investor confidence has been significantly ...

Investors are reassessing Viking Therapeutics' clinical trial data as concerns emerge about patient discontinuation rates in the study of oral ...

The obesity treatment market is becoming increasingly competitive as multiple pharmaceutical companies advance their GLP-1 receptor agonist candidates. Viking Therapeutics ...

Viking Therapeutics finds itself navigating significant market headwinds in the wake of recent clinical data presentations. The company's stock experienced ...

Shares of Viking Therapeutics experienced a dramatic sell-off after the biopharmaceutical company released Phase 2 trial results for its oral ...

Viking Therapeutics shares encountered selling pressure as the market digested Phase II trial data for its oral obesity treatment candidate ...

Viking Therapeutics finds itself at a pivotal juncture, navigating a complex landscape with a portfolio of promising metabolic disease treatments. ...

A notable institutional investor has established a new position in Viking Therapeutics, providing fresh momentum for the biopharmaceutical stock. This ...